Medicines

The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has two products in late stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. The Company's pipeline also includes a serine protease inhibitor, CU2010, in early-stage development.

Shares of The Medicines Company popped Monday after the biotech company announced positive results for its LDL cholesterol treatment in a pivotal study. Alnylam is a partner on the drug.

This Biotech Stock Just Put Up A Double-Digit Gain — Here's Why

Medicines Co. (MDCO) reported earnings 30 days ago.

Why Is Medicines Co. (MDCO) Down 1.2% Since Last Earnings Report?

The Medicines Company (NASDAQ: MDCO) stock has staged a nice recovery in the first half of 2019 after a steep 60% pullback in the second half of 2018 that dragged it to a 52-week low of $16.69 on Dec.

Biotech Stock On The Radar: Medicines Company, A Cardiovascular Pure Play With A Potential Blockbuster

Investors need to pay close attention to Medicines Company (MDCO) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Medicines Company (MDCO) Stock?

The Medicines Company (MDCO) posts narrower-than-expected loss in Q2. The company did not generate any revenues in the period while its focus is steady on its sole pipeline candidate, inclisiran.

Medicines Company (MDCO) Q2 Earnings Top, Inclisiran in View

The Medicines Company (MDCO) CEO Mark Timney on Q2 2019 Results - Earnings Call Transcript

Medicines Co. (MDCO) delivered earnings and revenue surprises of 4.55% and -100.00%, respectively, for the quarter ended June 2019.

Medicines Co. (MDCO) Reports Q2 Loss, Lags Revenue Estimates

AbbVie

Immunomedics

MGM Resorts

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Notable Insider Buys This Past Week: AbbVie, MGM and More

The Medicines Company (NASDAQ: MDCO) shares traded higher by 2.5 percent on Tuesday and are now up 7.5 percent overall in the past week.

These Bullish Medicines Company Options Trades Suggest More Upside Could Be Coming

Options Traders Expect Huge Moves in Medicines Company (MDCO) Stock

Zillow

Intrexon

Conventional wisdom says that insiders and 10 percent owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Notable Insider Buys This Past Week: Coty, Zillow and More

Bunge Global SA

Cognizant Technology Solutions

Hain Celestial Group

Insider buying can be an encouraging signal for potential investors. CEOs made notable purchases last week, with one of them bucking a selling trend.

Notable Insider Buys This Past Week: Bunge, Hain Celestial And More

Medicines Co. (MDCO) Up 17.1% Since Last Earnings Report: Can It Continue?

Small-cap biotech The Medicines Company announced long-term results over the weekend from a midstage study of its lead product candidate Inclisiran, sending its shares higher.

Medicines Company Rallies On Positive LDL Cholesterol Study Results

The Medicines Company (MDCO) suffers narrower-than-expected loss in Q1. The company progresses well with its sole pipeline candidate, inclisiran.

Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus

The Medicines Company (MDCO) CEO Mark Timney on Q1 2019 Results - Earnings Call Transcript

Medicines Co. (MDCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Medicines Co. (MDCO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Medicines Co. (MDCO) Up 12.9% Since Last Earnings Report: Can It Continue?

Arconic

CenturyLink

Kinder Morgan

Insider buying can be an encouraging signal for potential investors. An executive chair continuing making "very extreme" purchases in the past week.

News for Medicines Stock (MDCO)